USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On November 13, 2020, USA Equities Corp. (the “Company”) issued a press release announcing that an analyst report rating the Company was posted by Litchfield Hills Research LLC. The paid research report may be accessed at the following link:
A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.
The information in this Item 7.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. The information in this Item 7.01, including Exhibits 99.1, of this Form 8-K also shall not be deemed to be incorporated by reference into any filing under the Act or the Securities Exchange Act of 1934, except to the extent that we specifically incorporate it by reference.
ITEM 9.01 Financial Statements and Exhibits
| 99.1 | Press release entitled “Litchfield Hills Research Initiates Analyst Coverage of USA Equities Corp. (USAQ)” dated November 13, 2020 |
USA EQUITIES CORP. Exhibit
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Litchfield Hills Research Initiates Analyst Coverage of USA Equities Corp. (USAQ) West Palm Beach,…
To view the full exhibit click here
About USA EQUITIES CORP. (OTCMKTS:USAQ)
USA Equities Corp., formerly American Biogenetic Sciences, Inc., is a shell company. The Company focuses to seek new business opportunities, including seeking an acquisition or merger with an operating company. The Company’s subsidiary, USA Equities Trust, Inc., is engaged in acquiring real estate. The Company was engaged in the research, development and marketing of cardiovascular and neurobiology products for the purpose of commercial development and vaccines distribution. The Company’s products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Company has no operations.